Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease

Current Cardiology Reports

Volumn 1, Issue 3, 1999, Pages 233-237

  Ginsberg, Henry N ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

BLOOD; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE; MALE; META ANALYSIS; REVIEW; RISK FACTOR;

ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIFE STYLE; MALE; META-ANALYSIS; NIACIN; RISK FACTORS;

EID: 0033186117     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0028-6     Document Type: Article

References (30)

1. Austin MA: Plasma triglyceride and coronary heart disease. Arterioscler Thromb Vasc Biol 1991, 11:2-14.
2. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease: Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993, 269:505-510.
3. Hokanson JE, Austin MA: Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
4. Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998, 81(Suppl 4A):7B-12B.
5. Assman G, Schulte H, von Eckardstein A: Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996, 77:1179-1184.
6. Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992, 85:37-45.
7. Stampfer MJ, Krauss RM, Ma J, et al.: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996, 276:882-888.
8. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996, 276:875-881.
9. Miller BD, Alderman EL, Haskell WL, et al.: Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996, 94:2146-2153.
10. Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69-75.
11. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 1998, 97:1029-1036.
12. Zilversmit DB: Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem 1995, 41: 153-158.
13. Ginsberg HN, Jones J, Blaner WS, et al.: Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Bio 1995, 15:1829-1838.
14. Sharrett AR, Chambless LE, Heiss G, et al.: Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 1995, 15:2122-2129.
15. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
16. Laws A, Reaven GM: Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 1992, 231:25-30.
17. Despres J-P, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
18. Austin MA, Mykkanen L, Kuusisto J, et al.: Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995, 92:1770-1778.
19. Grundy SM, Vega GL: Two different views of the relationship of hypertriglyceridemia to coronary heart disease: implications for treatment. Arch Intern Med 1992, 152:28-34
20. Ginsberg HN: Is hypertriglyceridemia a risk factor for atherosclerotic cardiovascular disease? A simple question with a complicated answer. Ann Intern Med 1997, 126:912-914.
21. National Cholesterol Education Program: Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 1994, 89:1333-1445.
22. Grundy SM: Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997, 95:1-4.
23. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al.: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996, 275:128-33.
24. Davidson MH, Stein EA, Dujovne CA, et al.: The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997, 79:38-42.
25. Stein, EA, Lane, M. Laskarzewski P: Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998, 81(4A):66B-69B.
26. Ooi TC, Heinonen T, Alaupovic P, et al.: Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol 1997, 17:1793-1799.
27. Tikkanen MJ, Laakso M, Ilmonen M, et al.: Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes Care 1998, 21:477-481.
28. East C, Bilheimer DW, Grundy SM: Combination drug therapy for familial combined hyperlipidemia. Ann Int Med 1988, 109: 25-32.
29. Illingworth D F, Bacon S: Influence of lovastatin plus gemfibrozil on plasma lipids and l lipoproteins in patients with heterozygous familial hypercholesterolemia. Circulation 1989, 79:590-596.
30. Ellen RLB, and McPherson R: Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998, 81 (4A): 60B-65B.